BMC Women's Health (Nov 2010)

Cost-effectiveness of a screening strategy for Q fever among pregnant women in risk areas: a clustered randomized controlled trial

  • Lo-Ten-Foe Jerome R,
  • Meekelenkamp Jamie,
  • de Vries Esther,
  • Hamilton Carl JCM,
  • Stolk Ronald P,
  • Riphagen-Dalhuisen Josien,
  • Rietveld Ariene,
  • Schneeberger Peter M,
  • van der Hoek Wim,
  • Leenders Alexander CAP,
  • Munster Janna M,
  • Timmer Albertus,
  • De Jong - van den Berg Lolkje TW,
  • Aarnoudse Jan G,
  • Hak Eelko

DOI
https://doi.org/10.1186/1472-6874-10-32
Journal volume & issue
Vol. 10, no. 1
p. 32

Abstract

Read online

Abstract Background In The Netherlands the largest human Q fever outbreak ever reported in the literature is currently ongoing with more than 2300 notified cases in 2009. Pregnant women are particularly at risk as Q fever during pregnancy may cause maternal and obstetric complications. Since the majority of infected pregnant women are asymptomatic, a screening strategy might be of great value to reduce Q fever related complications. We designed a trial to assess the (cost-)effectiveness of a screening program for Q fever in pregnant women living in risks areas in The Netherlands. Methods/design We will conduct a clustered randomized controlled trial in which primary care midwife centres in Q fever risk areas are randomized to recruit pregnant women for either the control group or the intervention group. In both groups a blood sample is taken around 20 weeks postmenstrual age. In the intervention group, this sample is immediately analyzed by indirect immunofluorescence assay for detection of IgG and IgM antibodies using a sensitive cut-off level of 1:32. In case of an active Q fever infection, antibiotic treatment is recommended and serological follow up is performed. In the control group, serum is frozen for analysis after delivery. The primary endpoint is a maternal (chronic Q fever or reactivation) or obstetric complication (low birth weight, preterm delivery or fetal death) in Q fever positive women. Secondary aims pertain to the course of infection in pregnant women, diagnostic accuracy of laboratory tests used for screening, histo-pathological abnormalities of the placenta of Q fever positive women, side effects of therapy, and costs. The analysis will be according to the intention-to-screen principle, and cost-effectiveness analysis will be performed by comparing the direct and indirect costs between the intervention and control group. Discussion With this study we aim to provide insight into the balance of risks of undetected and detected Q fever during pregnancy. Trial registration ClinicalTrials.gov, protocol record NL30340.042.09.